BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, Bobbio-Pallavicini F, Murgo A, Balduzzi S, Caporali R, Montecucco C. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther 2020;22:290. [PMID: 33380344 DOI: 10.1186/s13075-020-02395-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhu Y, Zhong J, Dong L. Epidemiology and Clinical Management of Rheumatic Autoimmune Diseases in the COVID-19 Pandemic: A Review. Front Med (Lausanne) 2021;8:725226. [PMID: 34490312 DOI: 10.3389/fmed.2021.725226] [Reference Citation Analysis]
2 Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2021;59:5-30. [DOI: 10.47360/1995-4484-2021-5-30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 14.0] [Reference Citation Analysis]
3 Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, Schett G. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021;3:e724-36. [PMID: 34485930 DOI: 10.1016/S2665-9913(21)00247-2] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Bergman M, Saffore CD, Kim KJ, Patel PA, Garg V, Xuan S, Naik HB. Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis. Adv Ther 2021;38:5302-16. [PMID: 34515976 DOI: 10.1007/s12325-021-01906-4] [Reference Citation Analysis]
5 Specker C, Aries P, Braun J, Burmester G, Fischer-Betz R, Hasseli R, Holle J, Hoyer BF, Iking-Konert C, Krause A, Krüger K, Krusche M, Leipe J, Lorenz HM, Moosig F, Schmale-Grede R, Schneider M, Strangfeld A, Voll R, Voormann A, Wagner U, Schulze-Koops H. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. Z Rheumatol 2021. [PMID: 34491403 DOI: 10.1007/s00393-021-01055-7] [Reference Citation Analysis]
6 Moss P, Berenbaum F, Curigliano G, Grupper A, Berg T, Pather S. Benefit–Risk Evaluation of COVID-19 Vaccination in Special Population Groups of Interest. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.05.067] [Reference Citation Analysis]
7 Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 2021;10:323. [PMID: 33557301 DOI: 10.3390/cells10020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Favalli EG, Maioli G, Biggioggero M, Caporali R. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Rev Clin Immunol 2021;17:561-71. [PMID: 33787418 DOI: 10.1080/1744666X.2021.1908887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol 2021;:1-9. [PMID: 34860621 DOI: 10.1080/1744666X.2022.2014323] [Reference Citation Analysis]
10 Schreiber K, Graversgaard C, Petersen R, Jakobsen H, Bojesen AB, Krogh NS, Glintborg B, Hetland ML, Hendricks O. Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases-An Interim Report from a Danish Prospective Cohort Study. Vaccines (Basel) 2021;10:35. [PMID: 35062696 DOI: 10.3390/vaccines10010035] [Reference Citation Analysis]
11 Vogel F, Reincke M. Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. Rev Endocr Metab Disord 2021. [PMID: 34241765 DOI: 10.1007/s11154-021-09670-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Specker C, Aries P, Braun J, Burmester G, Fischer-Betz R, Hasseli R, Holle J, Hoyer BF, Iking-Konert C, Krause A, Krüger K, Krusche M, Leipe J, Lorenz HM, Moosig F, Schmale-Grede R, Schneider M, Strangfeld A, Voll R, Voormann A, Wagner U, Schulze-Koops H. [Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination]. Z Rheumatol 2021;80:570-87. [PMID: 34309739 DOI: 10.1007/s00393-021-01056-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Kondle S, Hou T, Manansala M, Ascoli C, Novak RM, Sweiss N. Treatment of COVID-19 in Patients With Sarcoidosis. Front Med (Lausanne) 2021;8:689539. [PMID: 34336892 DOI: 10.3389/fmed.2021.689539] [Reference Citation Analysis]
14 Ricciotti E, Laudanski K, FitzGerald GA. Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Adv Biol Regul 2021;81:100818. [PMID: 34303107 DOI: 10.1016/j.jbior.2021.100818] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Favalli EG, Gobbini A, Bombaci M, Maioli G, Biggioggero M, Pesce E, Favalli A, Martinovic M, Fabbris T, Marchisio E, Bandiera A, Gori A, Abrignani S, Grifantini R, Caporali R. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Front Med 2022;9:850858. [DOI: 10.3389/fmed.2022.850858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Favalli A, Favalli EG, Gobbini A, Zagato E, Bombaci M, Maioli G, Pesce E, Donnici L, Gruarin P, Biggioggero M, Curti S, Manganaro L, Marchisio E, Bevilacqua V, Martinovic M, Fabbris T, Sarnicola ML, Crosti M, Marongiu L, Granucci F, Notarbartolo S, Bandera A, Gori A, De Francesco R, Abrignani S, Caporali R, Grifantini R. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. Front Immunol 2022;13:873195. [PMID: 35757699 DOI: 10.3389/fimmu.2022.873195] [Reference Citation Analysis]
17 Ramirez GA, Argolini LM, Schioppo T, Sciascia S, Moroni L, Moroni G, Sinico RA, Bonelli G, Alberici F, Mescia F, Tamborini F, Miraglia P, Bellocchi C, Beretta L, Roccatello D, Bozzolo EP, Caporali R, Gerosa M, Dagna L; SMILE, Milan Lupus Consortium. Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination. Ann Rheum Dis 2022:annrheumdis-2022-222832. [PMID: 35922121 DOI: 10.1136/ard-2022-222832] [Reference Citation Analysis]
18 Caton E, Chaplin H, Carpenter L, Sweeney M, Tung HY, de Souza S, Galloway J, Nikiphorou E, Norton S. The impact of COVID-19 on self-management behaviours and healthcare access for people with inflammatory arthritis. BMC Rheumatol 2021;5:58. [PMID: 34657629 DOI: 10.1186/s41927-021-00231-1] [Reference Citation Analysis]
19 Lund LD, Løwe MM, Hendricks O, Schreiber K, Glintborg B, Petersen R, Plischke C, Fick W, Primdahl J. Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: “Reopening of Society Is Harder than Lock-Down”—A Qualitative Interview Study. Vaccines 2022;10:982. [DOI: 10.3390/vaccines10070982] [Reference Citation Analysis]
20 Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E. Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis. Vaccines (Basel) 2021;9:883. [PMID: 34452007 DOI: 10.3390/vaccines9080883] [Reference Citation Analysis]